Business Description
Founded in 2018 and headquartered in Dublin, Ireland, GH Research is a clinical-stage company working to bring new medicines to people suffering from serious mental health conditions. Its most advanced program, GH001, is an inhaled compound being studied in mid-stage trials for treatment-resistant depression, bipolar II disorder, and postpartum depression. The company is also investigating GH002, a version delivered through an IV line, currently in early-stage testing in healthy volunteers.
